St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).
Metal Implants Can Lead to Allergic Contact Dermatitis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions
Highlights from AAD 2023